Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenofovir

- PMLiVE

ViiV and Janssen take long-acting HIV regimen into phase III

Cabotegravir and rilpivirine injectable-therapy tipped as future blockbuster

EU flag

EU launches HIV action plan

Aims to "significantly contribute" to elimination of HIV in EU by 2020

- PMLiVE

ViiV and Janssen plan pivotal trials of monthly HIV treatment

Rilpivirine – cabotegravir combination could provide a monthly option

Gilead Sciences

Priority FDA review for new Gilead HCV combination therapy

Sovaldi/velpatasvir combination could be approved in the US by summer 2016

- PMLiVE

ViiV agrees $1.5bn deal to acquire BMS’ HIV assets

Includes its entire development pipeline - from discovery to preclinical projects

Gilead Sciences

Gilead steps into breach left by AbbVie as Galapagos’ partner

Deal worth $2bn to help rheumatoid arthritis drug filgotinib make it through to the market

Gilead Sciences

Gilead’s HIV drug Genvoya cleared in EU

First TAF-based regimen to be approved in the US and EU

Bristol-Myers Squibb (BMS) building

First data backs efficacy of BMS’ novel HIV drug

Could provide new treatment for those resistant to antiretroviral therapy

National Institute for Health and Care Excellence NICE logo

NICE backs three hepatitis C meds, turns down Duchenne drug

Benefits of short treatments with high cure rates reinforces drugs value

Gilead Sciences

Gilead receives FDA approval for PAH combo

Letairis with tadalafil given the nod for pulmonary arterial hypertension

- PMLiVE

Novartis to make 15 drugs available at $1 a month

Comes after concerns surrounding hiked drug prices and effects on public health

National Institute for Health and Care Excellence NICE logo

NICE gives nod to Gilead’s Zydelig

First class of drug to be recommended for leukaemia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links